Investigating how monoclonal antibodies behave at different interfaces to improve treatments for viral infections.
Official title: Probing in situ higher order structures of monoclonal antibodies at water-air and water-oil interfaces via high-field nuclear magnetic resonance spectroscopy for viral infections
Funded at Florida State University · NIH-10909013 · Data updated 2026-11-12
This study is looking at how certain treatments, called monoclonal antibodies, behave when they touch surfaces like IV bags and syringes, which is important for making sure these treatments work well and are safe for people with conditions like COVID-19 and cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida State University NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project start | August 17, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $189,456 |
| NIH project number | 5R21AI163988-02 |
| Project ID | NIH-10909013 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients receiving monoclonal antibody treatments for conditions such as COVID-19, cancer, or other infectious diseases.
✕Less likely to help
Patients who are not receiving monoclonal antibody therapies or those with conditions unrelated to the focus of this research may not benefit.
What this research studies
This research focuses on understanding the behavior of monoclonal antibodies (mAbs) when they come into contact with hydrophobic surfaces, such as those found in IV bags and syringes. By using advanced nuclear magnetic resonance (NMR) spectroscopy, the study aims to evaluate the structural integrity of mAbs at these interfaces, which is crucial for ensuring their effectiveness and safety in treating conditions like COVID-19 and cancer. The research will explore how mAbs may change their structure when adsorbed to these surfaces, potentially affecting their therapeutic properties. This innovative approach seeks to overcome previous limitations in studying mAb behavior at a microscopic level.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective monoclonal antibody therapies for patients with viral infections and other diseases.
How similar studies have gone: While the approach of using high-field NMR spectroscopy for this purpose is innovative, similar studies have shown promise in understanding protein behavior at interfaces.
Where this research is happening
-
Florida State University
Tallahassee, United States Active
Researchers
- Principal investigator: Mohammadigoushki, Hadi — Florida State University
- Study coordinator: Mohammadigoushki, Hadi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.